|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
215 a.a.
|
 |
|
|
|
|
|
|
|
228 a.a.
|
 |
|
|
|
|
|
|
|
11 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Igg1 fab fragment (58.2) complex with 12-residue cyclic peptide (including residues 315-324 of HIV-1 gp120 (mn isolate); h315s mutation
|
|
Structure:
|
 |
Protein (immunoglobulin gamma i (58.2)). Chain: l. Fragment: light chain of fab. Synonym: fab 58.2. Protein (immunoglobulin gamma i (58.2)). Chain: h. Fragment: heavy chain of fab. Synonym: fab 58.2. Protein (cyclic peptide (gp120)).
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Strain: balb/c. Synthetic: yes. Other_details: 12 residue hydrazone-linked cyclic peptide was chemically synthesized from residues 316-324 of HIV-1 gp120 strain mn.
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
|
Authors:
|
 |
R.L.Stanfield,E.Cabezas,A.C.Satterthwait,E.A.Stura,A.T.Profy, I.A.Wilson
|
Key ref:
|
 |
R.Stanfield
et al.
(1999).
Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.
Structure,
7,
131-142.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-Oct-98
|
Release date:
|
09-Feb-99
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Structure
7:131-142
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.
|
|
R.Stanfield,
E.Cabezas,
A.Satterthwait,
E.Stura,
A.Profy,
I.Wilson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: The third hypervariable (V3) loop of HIV-1 gp120 has been termed the
principal neutralizing determinant (PND) of the virus and is involved in many
aspects of virus infectivity. The V3 loop is required for viral entry into the
cell via membrane fusion and is believed to interact with cell surface chemokine
receptors on T cells and macrophages. Sequence changes in V3 can affect
chemokine receptor usage, and can, therefore, modulate which types of cells are
infected. Antibodies raised against peptides with V3 sequences can neutralize
laboratory-adapted strains of the virus and inhibit syncytia formation. Fab
fragments of these neutralizing antibodies in complex with V3 loop peptides have
been studied by X-ray crystallography to determine the conformation of the V3
loop. RESULTS: We have determined three crystal structures of Fab 58.2, a
broadly neutralizing antibody, in complex with one linear and two cyclic
peptides the amino acid sequence of which comes from the MN isolate of the gp120
V3 loop. Although the peptide conformations are very similar for the linear and
cyclic forms, they differ from that seen for the identical peptide bound to a
different broadly neutralizing antibody, Fab 59.1, and for a similar peptide
bound to the MN-specific Fab 50.1. The conformational difference in the peptide
is localized around residues Gly-Pro-Gly-Arg, which are highly conserved in
different HIV-1 isolates and are predicted to adopt a type II beta turn.
CONCLUSIONS: The V3 loop can adopt at least two different conformations for the
highly conserved Gly-Pro-Gly-Arg sequence at the tip of the loop. Thus, the
HIV-1 V3 loop has some inherent conformational flexibility that may relate to
its biological function.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 2.
Figure 2. Stereoviews of the X-ray structures of the Fab
58.2–peptide complexes. (a) The Fab 58.2–Aib142 complex. The
Cα trace is shown for the light chain (cyan) and heavy chain
(blue) of the Fab. All atoms of the bound peptide are shown in
red. Every tenth Cα atom is highlighted with a sphere and some
atoms are labeled. (b) The Fab 58.2–His loop complex. (c) The
Fab 58.2–Ser loop complex. Figures were made with the program
MOLSCRIPT [74] .
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from Cell Press:
Structure
(1999,
7,
131-142)
copyright 1999.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.N.Dybowski,
D.Heider,
and
D.Hoffmann
(2010).
Prediction of co-receptor usage of HIV-1 from genotype.
|
| |
PLoS Comput Biol,
6,
e1000743.
|
 |
|
|
|
|
 |
A.Mor,
E.Segal,
B.Mester,
B.Arshava,
O.Rosen,
F.X.Ding,
J.Russo,
A.Dafni,
F.Schvartzman,
T.Scherf,
F.Naider,
and
J.Anglister
(2009).
Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.
|
| |
Biochemistry,
48,
3288-3303.
|
 |
|
|
|
|
 |
K.L.Longenecker,
Q.Ruan,
E.H.Fry,
S.C.Saldana,
S.E.Brophy,
P.L.Richardson,
and
S.Y.Tetin
(2009).
Crystal structure and thermodynamic analysis of diagnostic mAb 106.3 complexed with BNP 5-13 (C10A).
|
| |
Proteins,
76,
536-547.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.A.Galanakis,
N.G.Kandias,
A.K.Rizos,
D.Morikis,
E.Krambovitis,
and
G.A.Spyroulias
(2009).
NMR evidence of charge-dependent interaction between various PND V3 and CCR5 N-terminal peptides.
|
| |
Biopolymers,
92,
94.
|
 |
|
|
|
|
 |
R.Pejchal,
J.S.Gach,
F.M.Brunel,
R.M.Cardoso,
R.L.Stanfield,
P.E.Dawson,
D.R.Burton,
M.B.Zwick,
and
I.A.Wilson
(2009).
A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.
|
| |
J Virol,
83,
8451-8462.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.K.Dhillon,
R.L.Stanfield,
M.K.Gorny,
C.Williams,
S.Zolla-Pazner,
and
I.A.Wilson
(2008).
Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.
|
| |
Acta Crystallogr D Biol Crystallogr,
64,
792-802.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.H.Bell,
R.Pantophlet,
A.Schiefner,
L.A.Cavacini,
R.L.Stanfield,
D.R.Burton,
and
I.A.Wilson
(2008).
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
|
| |
J Mol Biol,
375,
969-978.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.K.Goh,
A.K.Dunker,
and
V.N.Uversky
(2008).
Protein intrinsic disorder toolbox for comparative analysis of viral proteins.
|
| |
BMC Genomics,
9,
S4.
|
 |
|
|
|
|
 |
J.Gu,
and
J.S.Liu
(2008).
Bayesian biclustering of gene expression data.
|
| |
BMC Genomics,
9,
S4.
|
 |
|
|
|
|
 |
N.Krauss,
H.Wessner,
K.Welfle,
H.Welfle,
C.Scholz,
M.Seifert,
K.Zubow,
J.Aÿ,
M.Hahn,
P.Scheerer,
A.Skerra,
and
W.Höhne
(2008).
The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops.
|
| |
Proteins,
73,
552-565.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.P.Troth,
A.D.Dean,
and
E.A.Hoover
(2008).
In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.
|
| |
Vet Immunol Immunopathol,
123,
97.
|
 |
|
|
|
|
 |
F.W.Peyerl,
S.Dai,
G.A.Murphy,
F.Crawford,
J.White,
P.Marrack,
and
J.W.Kappler
(2007).
Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex.
|
| |
Cell Death Differ,
14,
447-452.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.Pantophlet,
R.O.Aguilar-Sino,
T.Wrin,
L.A.Cavacini,
and
D.R.Burton
(2007).
Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
|
| |
Virology,
364,
441-453.
|
 |
|
|
|
|
 |
T.Cardozo,
T.Kimura,
S.Philpott,
B.Weiser,
H.Burger,
and
S.Zolla-Pazner
(2007).
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.
|
| |
AIDS Res Hum Retroviruses,
23,
415-426.
|
 |
|
|
|
|
 |
A.M.Andrianov,
and
V.G.Veresov
(2006).
Determination of structurally conservative amino acids of the HIV-1 protein gp120 V3 loop as promising targets for drug design by protein engineering approaches.
|
| |
Biochemistry (Mosc),
71,
906-914.
|
 |
|
|
|
|
 |
C.Pastore,
R.Nedellec,
A.Ramos,
S.Pontow,
L.Ratner,
and
D.E.Mosier
(2006).
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
|
| |
J Virol,
80,
750-758.
|
 |
|
|
|
|
 |
T.Watabe,
H.Kishino,
Y.Okuhara,
and
Y.Kitazoe
(2006).
Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host.
|
| |
Genetics,
172,
1385-1396.
|
 |
|
|
|
|
 |
O.Hartley,
P.J.Klasse,
Q.J.Sattentau,
and
J.P.Moore
(2005).
V3: HIV's switch-hitter.
|
| |
AIDS Res Hum Retroviruses,
21,
171-189.
|
 |
|
|
|
|
 |
R.M.Cardoso,
M.B.Zwick,
R.L.Stanfield,
R.Kunert,
J.M.Binley,
H.Katinger,
D.R.Burton,
and
I.A.Wilson
(2005).
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
|
| |
Immunity,
22,
163-173.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
V.N.Uversky,
C.J.Oldfield,
and
A.K.Dunker
(2005).
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.
|
| |
J Mol Recognit,
18,
343-384.
|
 |
|
|
|
|
 |
P.D.Kwong
(2004).
The 447-52D antibody: hitting HIV-1 where its armor is thickest.
|
| |
Structure,
12,
173-174.
|
 |
|
|
|
|
 |
R.L.Stanfield,
M.K.Gorny,
C.Williams,
S.Zolla-Pazner,
and
I.A.Wilson
(2004).
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.
|
| |
Structure,
12,
193-204.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.T.Hsu,
and
A.M.Bonvin
(2004).
Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120.
|
| |
Proteins,
55,
582-593.
|
 |
|
|
|
|
 |
R.Pantophlet,
and
D.R.Burton
(2003).
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies.
|
| |
Trends Mol Med,
9,
468-473.
|
 |
|
|
|
|
 |
J.Ding,
A.D.Smith,
S.C.Geisler,
X.Ma,
G.F.Arnold,
and
E.Arnold
(2002).
Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1.
|
| |
Structure,
10,
999.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.K.Gorny,
C.Williams,
B.Volsky,
K.Revesz,
S.Cohen,
V.R.Polonis,
W.J.Honnen,
S.C.Kayman,
C.Krachmarov,
A.Pinter,
and
S.Zolla-Pazner
(2002).
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
|
| |
J Virol,
76,
9035-9045.
|
 |
|
|
|
|
 |
D.Jain,
K.J.Kaur,
and
D.M.Salunke
(2001).
Plasticity in protein-peptide recognition: crystal structures of two different peptides bound to concanavalin A.
|
| |
Biophys J,
80,
2912-2921.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Poignard,
E.O.Saphire,
P.W.Parren,
and
D.R.Burton
(2001).
gp120: Biologic aspects of structural features.
|
| |
Annu Rev Immunol,
19,
253-274.
|
 |
|
|
|
|
 |
W.F.Vranken,
F.Fant,
M.Budesinsky,
and
F.A.Borremans
(2001).
Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution.
|
| |
Eur J Biochem,
268,
2620-2628.
|
 |
|
|
|
|
 |
A.Zvi,
V.Tugarinov,
G.A.Faiman,
A.Horovitz,
and
J.Anglister
(2000).
A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.
|
| |
Eur J Biochem,
267,
767-779.
|
 |
|
|
|
|
 |
J.Su,
A.Palm,
Y.Wu,
S.Sandin,
S.Höglund,
and
A.Vahlne
(2000).
Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells.
|
| |
AIDS Res Hum Retroviruses,
16,
37-48.
|
 |
|
|
|
|
 |
P.D.Kwong,
R.Wyatt,
Q.J.Sattentau,
J.Sodroski,
and
W.A.Hendrickson
(2000).
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
|
| |
J Virol,
74,
1961-1972.
|
 |
|
|
|
|
 |
V.Tugarinov,
A.Zvi,
R.Levy,
Y.Hayek,
S.Matsushita,
and
J.Anglister
(2000).
NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding.
|
| |
Structure,
8,
385-395.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |
|